GlassScriptPhysician profile
Amy Zhang
NPI 1861811952
$7,580.81
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $81.58 · 2021: $106 · 2022: $2,616 · 2023: $1,100 · 2024: $3,110 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Consulting Fee: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.14 |
| Consulting Fee | $1,890.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,160.83 | 2021-2025 | Tremfya |
| Amgen INC. | $476.73 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $439.72 | 2022-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $400.40 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $320.63 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $281.70 | 2020-2024 | Taltz |
| Genentech USA, INC. | $218.85 | 2023-2025 | Actemra |
| Ucb, INC. | $185.50 | 2022-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $177.26 | 2022-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $102.48 | 2022-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $101.27 | 2022-2023 | Purified Cortrophin Gel |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $91.81 | 2021-2024 | Lupkynis |
| Pfizer INC. | $90.21 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $85.68 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.29 | 2023-2024 | Cyltezo |
| Sandoz INC. | $57.70 | 2023-2024 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $45.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.76 | 2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $38.90 | 2024 | Strensiq |
| Genzyme Corporation | $27.78 | 2023-2025 | |
| Radius Health, INC. | $19.50 | 2025 | |
| Kyowa Kirin, INC. | $19.23 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $18.06 | 2025 | Hyqvia |
| Ultragenyx Pharmaceutical INC. | $13.74 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.